Expanding Horizons: Pioneering Healthcare Innovation

From humble beginnings as a contract manufacturer for industry leaders, this company has come a long way. Now, the company is strategically transitioning from a B2B model to a B2B2C approach, offering a diverse array of healthcare solutions. They are focusing on branded segments like Petcare, Nutrition, and Cosmetics. They have set ambitious targets, aiming for a robust 25-30% CAGR growth between FY24 to FY26, while maintaining a healthy EBITDA margin of 12-15%. Currently trading at a multiple of 25x FY24 earnings, the stock presents an enticing opportunity, considering its strong growth prospects.